BRPI0711908B8 - anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo. - Google Patents
anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.Info
- Publication number
- BRPI0711908B8 BRPI0711908B8 BRPI0711908A BRPI0711908A BRPI0711908B8 BR PI0711908 B8 BRPI0711908 B8 BR PI0711908B8 BR PI0711908 A BRPI0711908 A BR PI0711908A BR PI0711908 A BRPI0711908 A BR PI0711908A BR PI0711908 B8 BRPI0711908 B8 BR PI0711908B8
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- interleukin
- producing
- pharmaceutical composition
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Analytical Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
Abstract
anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, métodos de tratamento de um paciente humano afetado com uma doença auto-imune, de produção de um anticorpo e de seleção de um anticorpo. a presente invenção descreve anticorpos anti-il- 18 humanizados, métodos de fabricação e métodos de tratamento com referidos anticorpos. ainda são descritos os métodos de triagem usando, por exemplo, ressonância de plasmon de superfície para identificar anticorpos com potencial terapêutico.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0610438.4 | 2006-05-25 | ||
| GB0610438A GB0610438D0 (en) | 2006-05-25 | 2006-05-25 | Immunoglobulins |
| GB0611046.4 | 2006-06-05 | ||
| GB0611046A GB0611046D0 (en) | 2006-06-05 | 2006-06-05 | Immunoglobulins |
| PCT/EP2007/055029 WO2007137984A2 (en) | 2006-05-25 | 2007-05-23 | Modified humanised anti-interleukin-18 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0711908A2 BRPI0711908A2 (pt) | 2012-01-03 |
| BRPI0711908B1 BRPI0711908B1 (pt) | 2020-08-04 |
| BRPI0711908B8 true BRPI0711908B8 (pt) | 2021-05-25 |
Family
ID=38476914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0711908A BRPI0711908B8 (pt) | 2006-05-25 | 2007-05-23 | anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo. |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US8133978B2 (pt) |
| EP (1) | EP2027157B1 (pt) |
| JP (1) | JP5420399B2 (pt) |
| KR (1) | KR101416078B1 (pt) |
| AR (1) | AR061115A1 (pt) |
| AU (1) | AU2007267213B2 (pt) |
| BR (1) | BRPI0711908B8 (pt) |
| CA (1) | CA2652733C (pt) |
| CR (1) | CR10468A (pt) |
| EA (1) | EA017303B1 (pt) |
| ES (1) | ES2514495T3 (pt) |
| IL (1) | IL194995A0 (pt) |
| MA (1) | MA30486B1 (pt) |
| MX (1) | MX2008014842A (pt) |
| MY (1) | MY157173A (pt) |
| NO (1) | NO341921B1 (pt) |
| NZ (1) | NZ572565A (pt) |
| PE (1) | PE20080262A1 (pt) |
| SG (1) | SG172625A1 (pt) |
| TW (1) | TWI422387B (pt) |
| WO (1) | WO2007137984A2 (pt) |
| ZA (1) | ZA200809662B (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| AU2007267213B2 (en) * | 2006-05-25 | 2012-03-29 | Glaxo Group Limited | Modified humanised anti-interleukin-18 antibodies |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| EP3415529B1 (en) | 2007-09-26 | 2020-11-04 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| EP2326315A1 (en) * | 2008-08-18 | 2011-06-01 | Glaxo Group Limited | Treatment of an autoimmune disease using il-18 antagonists |
| EP2685238B1 (en) | 2008-08-27 | 2018-06-13 | F. Hoffmann-La Roche AG | Method to screen high affinity antibody |
| TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| WO2010040736A2 (en) * | 2008-10-07 | 2010-04-15 | Ablynx Nv | Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
| SG178546A1 (en) | 2009-08-25 | 2012-03-29 | Hoffmann La Roche | Velocity factor |
| US20120308564A1 (en) * | 2010-02-09 | 2012-12-06 | Andrew Ian Bayliffe | Treatment of a metabolic disorder |
| PH12012501991A1 (en) | 2010-04-07 | 2017-07-26 | Abbvie Inc | Tnf-alpha binding proteins |
| EP2643352B1 (en) * | 2010-11-23 | 2018-05-02 | Glaxo Group Limited | Antigen binding proteins to oncostatin m (osm) |
| TWI654204B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| US20130149308A1 (en) * | 2011-08-12 | 2013-06-13 | Genentech, Inc. | Antibodies to il-1beta and il-18, for treatment of disease |
| US9376489B2 (en) | 2012-09-07 | 2016-06-28 | Novartis Ag | IL-18 binding molecules |
| ES2742413T3 (es) | 2012-11-21 | 2020-02-14 | Km Biologics Co Ltd | Nuevo anticuerpo humano contra IL-18 |
| JP2016519145A (ja) * | 2013-05-15 | 2016-06-30 | メディミューン リミテッド | 組換え産生ポリペプチドの精製 |
| WO2014200018A1 (ja) | 2013-06-11 | 2014-12-18 | 独立行政法人 国立精神・神経医療研究センター | 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法 |
| TWI873632B (zh) | 2015-02-27 | 2025-02-21 | 日商中外製藥股份有限公司 | Il-6受體抗體用於製備醫藥組成物的用途 |
| PL3299810T3 (pl) | 2015-05-19 | 2021-12-13 | National Center Of Neurology And Psychiatry | Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm) |
| WO2017076805A1 (en) * | 2015-11-02 | 2017-05-11 | Glaxosmithkline Intellectual Property Development Limited | Use of an inhibitor of il18 for treatment of acute kidney injury |
| US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
| US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| WO2020213665A1 (ja) | 2019-04-17 | 2020-10-22 | 国立大学法人広島大学 | Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤 |
| WO2021206766A1 (en) | 2020-04-09 | 2021-10-14 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| US11324750B2 (en) | 2020-04-09 | 2022-05-10 | Children's Hospital Medical Center | Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection |
| EP3892280A3 (en) | 2020-04-09 | 2022-01-12 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| TWI872251B (zh) | 2020-05-29 | 2025-02-11 | 日商中外製藥股份有限公司 | 含有抗體製劑 |
| IL301263A (en) | 2020-11-18 | 2023-05-01 | Novartis Ag | BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF NLRC4-GOF INFLAMMASOMAPATHY |
| EP4371573A4 (en) | 2021-07-13 | 2025-08-20 | National Univ Corporation Tokai National Higher Education And Research System | MEDICINAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE |
| US20240425560A1 (en) * | 2021-09-29 | 2024-12-26 | Chimera Bioengineering, Inc. | IL-18 Variants and Uses Thereof |
| CN121586728A (zh) | 2023-06-20 | 2026-02-27 | 阿波罗Ap43有限公司 | 用于治疗特应性皮炎的抗il-18抗体疗法 |
| WO2025229563A1 (en) * | 2024-05-03 | 2025-11-06 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating inflammatory bowel disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| ES2134212T3 (es) * | 1991-04-25 | 1999-10-01 | Chugai Pharmaceutical Co Ltd | Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano. |
| ES2145004T3 (es) | 1991-08-21 | 2000-07-01 | Novartis Ag | Derivados de anticuerpos. |
| GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| US6048972A (en) * | 1994-07-13 | 2000-04-11 | Chugai Pharmaceutical Co., Ltd. | Recombinant materials for producing humanized anti-IL-8 antibodies |
| DE69519454T2 (de) | 1994-07-14 | 2001-05-03 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama | Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen |
| TW581771B (en) | 1994-11-15 | 2004-04-01 | Hayashibara Biochem Lab | Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide |
| JP2952750B2 (ja) * | 1995-02-23 | 1999-09-27 | 株式会社林原生物化学研究所 | モノクローナル抗体 |
| DE69832970T2 (de) * | 1997-04-07 | 2006-08-10 | Genentech, Inc., South San Francisco | Humanisierte antikörper und verfahren zu ihrer herstellung |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| CA2276216A1 (en) | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
| AR022952A1 (es) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
| PL356836A1 (en) * | 2000-02-10 | 2004-07-12 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| NZ535299A (en) | 2000-02-21 | 2006-06-30 | Applied Research Systems | Use of IL-18 inhibitors |
| US20020025317A1 (en) | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
| TR200300478T2 (tr) * | 2000-10-13 | 2004-10-21 | Biogen Inc. | Hümanize antiLT-ß-R antikorları |
| AU2002224417A1 (en) | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| US20050074434A1 (en) | 2001-02-23 | 2005-04-07 | Tomoaki Hoshino | Remedies for metabolic bone diseases |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| UA78516C2 (en) | 2001-08-10 | 2007-04-10 | Applied Research Systems | Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity |
| CA2523912A1 (en) | 2003-04-30 | 2004-11-11 | Japan Science And Technology Agency | Human antihuman interleukin-18 antibody, fragment thereof and method of using the same |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| US7968684B2 (en) * | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| SI1730191T1 (sl) * | 2004-03-30 | 2011-11-30 | Glaxo Group Ltd | Imunoglobulin-vezavni hOSM |
| GB0425556D0 (en) | 2004-11-19 | 2004-12-22 | Glaxo Group Ltd | Novel compounds |
| GB0600488D0 (en) | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
| EP1987066B1 (en) | 2006-02-22 | 2010-12-29 | University of Zürich | Methods for treating demyelinating diseases |
| AU2007267213B2 (en) * | 2006-05-25 | 2012-03-29 | Glaxo Group Limited | Modified humanised anti-interleukin-18 antibodies |
| EP2326315A1 (en) | 2008-08-18 | 2011-06-01 | Glaxo Group Limited | Treatment of an autoimmune disease using il-18 antagonists |
-
2007
- 2007-05-23 AU AU2007267213A patent/AU2007267213B2/en not_active Ceased
- 2007-05-23 MY MYPI20084745A patent/MY157173A/en unknown
- 2007-05-23 MX MX2008014842A patent/MX2008014842A/es active IP Right Grant
- 2007-05-23 US US11/752,707 patent/US8133978B2/en active Active
- 2007-05-23 CA CA2652733A patent/CA2652733C/en active Active
- 2007-05-23 KR KR1020087031233A patent/KR101416078B1/ko not_active Expired - Fee Related
- 2007-05-23 PE PE2007000638A patent/PE20080262A1/es not_active Application Discontinuation
- 2007-05-23 WO PCT/EP2007/055029 patent/WO2007137984A2/en not_active Ceased
- 2007-05-23 BR BRPI0711908A patent/BRPI0711908B8/pt active IP Right Grant
- 2007-05-23 EP EP07786719.0A patent/EP2027157B1/en active Active
- 2007-05-23 ES ES07786719.0T patent/ES2514495T3/es active Active
- 2007-05-23 NZ NZ572565A patent/NZ572565A/en not_active IP Right Cessation
- 2007-05-23 SG SG2011037421A patent/SG172625A1/en unknown
- 2007-05-23 JP JP2009511524A patent/JP5420399B2/ja active Active
- 2007-05-23 AR ARP070102237A patent/AR061115A1/es not_active Application Discontinuation
- 2007-05-23 TW TW096118442A patent/TWI422387B/zh not_active IP Right Cessation
- 2007-05-23 EA EA200802182A patent/EA017303B1/ru not_active IP Right Cessation
-
2008
- 2008-10-30 IL IL194995A patent/IL194995A0/en unknown
- 2008-11-05 NO NO20084650A patent/NO341921B1/no unknown
- 2008-11-12 ZA ZA2008/09662A patent/ZA200809662B/en unknown
- 2008-11-27 CR CR10468A patent/CR10468A/es unknown
- 2008-12-01 MA MA31429A patent/MA30486B1/fr unknown
-
2011
- 2011-12-09 US US13/315,358 patent/US8637018B2/en active Active
-
2013
- 2013-12-19 US US14/133,751 patent/US9499617B2/en active Active
-
2016
- 2016-10-14 US US15/293,823 patent/US20170029497A1/en not_active Abandoned
-
2018
- 2018-10-16 US US16/161,175 patent/US10703814B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY157173A (en) | Modified humanised anti-interleukin-18 | |
| CL2021003290A1 (es) | Anticuerpos de unión a cd3. (divisional de solicitud 201900643) | |
| EA200970262A1 (ru) | Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| UA116614C2 (uk) | Антитіло до фактора d і його застосування | |
| EA030259B8 (ru) | Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf | |
| AR059922A1 (es) | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos | |
| AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
| BR112013027829A2 (pt) | anticorpos anti-cd40 e método de uso | |
| BRPI0508716A (pt) | anticorpo monoclonal, processo para produzir o mesmo, composição farmacêutica, e, uso de um anticorpo monoclonal | |
| MY149630A (en) | Antibodies against amyloid-beta peptide | |
| MX2019004692A (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos. | |
| UY29284A1 (es) | Anticuerpos ab(beta) humanizados usados en mejorar la cognicion | |
| AR051528A1 (es) | Anticuerpos humanizados que reconocen el peptido beta amiloideo | |
| BRPI0622073A8 (pt) | Uso de anticorpos pdgfralfa para fabricação de um medicamento para tratar um tumor ósseo | |
| BRPI0607486A2 (pt) | anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos | |
| CR9512A (es) | Metodos para el tratamiento de tumores de cerebro con anticuerpos | |
| CY1115572T1 (el) | Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου | |
| TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
| CR9562A (es) | Anticuerpos anti-cd40 humanizados y sus metodos de uso | |
| EA200900177A1 (ru) | Замещенные ациланилиды и способы их применения | |
| AR052285A1 (es) | Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas | |
| AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| CR8698A (es) | Anticuerpos monoclonales al factor de crecimiento de hepatocito | |
| ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25G | Requested change of headquarter approved |
Owner name: GLAXO GROUP LIMITED (GB) |